Combating endometriosis by blocking proteasome and nuclear factor-kappa B pathways

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F09%3A00010914" target="_blank" >RIV/61989592:15310/09:00010914 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Combating endometriosis by blocking proteasome and nuclear factor-kappa B pathways
Original language description
I have read with great interest the article by Celik et al. (2008) regarding experimental treatment of mouse endometriosis by inhibiting proteasome and nuclear factor-kB (NF-kB). The findings are in good concordance with recent works suggesting NF-kB tobe a major factor in the pathogenesis of endometriosis (Guo, 2007). In fact, pyrrolidine dithiocarbamate (PDTC) and other dithiocarbamates are NF-kB inhibitors because of creating copper complexes in the body and inhibiting proteasome (Cvek and Dvorak, 2007); hence, PDTC is proteasome inhibitor as well as bortezomib. On the other hand, bortezomib as a proteasome inhibitor inhibits NF-kB pathway as well in humans (Orlowski and Kuhn, 2008).
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FK - Gynaecology and obstetrics
OECD FORD branch
—

Project
<a href="/en/project/GP303%2F08%2FP137" target="_blank" >GP303/08/P137: Influence of dithiocarbamate complexes with Pt(II) and Au(III) on NF-?B pathway in human tumor lines HepG2 and SK-HEP-1</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2009
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)